ZipBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ZipBio is a private, preclinical-stage biotech founded in 2023, pioneering a novel approach to drug discovery through its proprietary COMPACT platform. The platform uses generative AI to design compact, multispecific therapeutic proteins that overcome the size and delivery limitations of traditional biologics, enabling targeting of complex, multi-pathway diseases. The company is building an internal pipeline, with a lead ophthalmology program targeting clinical trials in 2026, and is also exploring external partnerships. Backed by experienced founders and advisors with deep expertise in medicine, protein design, and drug development, ZipBio is positioned at the intersection of AI and biologics to create a new class of smart therapeutics.

Ophthalmology

Technology Platform

COMPACT: A proprietary generative AI platform that designs de novo, compact, multifunctional therapeutic proteins ('Zip drugs') by compressing complex biological structures while retaining full functionality, aimed at intractable targets.

Opportunities

ZipBio's technology could unlock a vast market of 'undruggable' targets in complex diseases like retinal disorders, creating first-in-class therapies.

The specific focus on ophthalmology addresses a high-need area where compact, multi-specific drugs could revolutionize invasive treatment paradigms.

Successful platform validation could also enable lucrative partnerships across multiple therapeutic areas.

Risk Factors

The core scientific risk is high, as the platform's ability to reliably design safe and effective de novo proteins in humans is unproven.

The company faces intense competition from well-funded AI biotechs and must successfully transition from preclinical research to clinical trials.

As a pre-revenue startup, it is dependent on future fundraising in a volatile capital environment.

Competitive Landscape

ZipBio competes in the crowded and rapidly evolving AI-driven drug discovery sector, facing companies like Generate Biomedicines, Absci, and Recursion that also employ generative AI for protein design. Its specific focus on 'compression' for ocular delivery is a niche differentiator, but it must compete for talent, funding, and partnerships against players with greater resources and later-stage pipelines.

More companies in AI / Machine Learning →More companies in United States →